2019 Future of Scar R&D Pipeline Drugs and Companies- Analysis of Global Scar Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

January 2019 | 75 pages | ID: 24DFFA636EFEN
VPAResearch

Abstracts

The global demand for Scar treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Scar pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Scar pipeline companies from advancing their products into Phase 3 or Phase 4.

Scar Report Description

The H1 2019 pipeline review report on Scar pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Scar pipeline compounds.

The Scar pipeline guide presents information on all active drugs currently being developed for Scar. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Scar pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Scar drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Scar product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Scar pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Scar pipeline report includes

• An overview of Scar disease including symptoms, causes, diagnosis and available treatment options is provided.
• Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
• Phase wise count of pipeline compounds
• Company wise list of pipeline compounds
• Mechanism of Action wise pipeline compounds
• For each pipeline product, the following details are provided-
• Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
• Current status of development
• Drug overview
• Mechanism of Action
• Pre-clinical and Clinical Trials

REASONS TO BUY

• The report is designed to help industry executives promote the success and continued growth of their organizations
• Get clear understanding of the entire Scar pipeline, with details on active projects
• Stay ahead of the competition through comprehensive knowledge of Scar pipeline progress
• Get in detail information of each product with updated information on each project along with key milestones
• Gain clear insights into the market through in-depth strategic analysis review
• Know the list of companies participating in global Scar pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2. GLOBAL SCAR PIPELINE OVERVIEW

2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology

3. EXECUTIVE SUMMARY

3.1 Scar Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Scar pipeline, H1- 2019
3.5 Mechanism of Action wise Scar Pipeline Candidates

4. ADETHERAPEUTICS INC SCAR PIPELINE DETAILS

4.1 AdeTherapeutics Inc Business Profile
4.2 AdeTherapeutics Inc Scar Drug Details
  4.2.1 Drug Snapshot
    4.2.1.1 Originator
    4.2.1.2 Collaborator/Co-Developer
    4.2.1.3 Route of Administration
    4.2.1.4 Orphan Drug/Fast Track/Special Designation
    4.2.1.5 Area
    4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5. ALTACOR LTD SCAR PIPELINE DETAILS

5.1 Altacor Ltd Business Profile
5.2 Altacor Ltd Scar Drug Details
  5.2.1 Drug Snapshot
    5.2.1.1 Originator
    5.2.1.2 Collaborator/Co-Developer
    5.2.1.3 Route of Administration
    5.2.1.4 Orphan Drug/Fast Track/Special Designation
    5.2.1.5 Area
    5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6. BIRCHBIOMED INC SCAR PIPELINE DETAILS

6.1 BirchBioMed Inc Business Profile
6.2 BirchBioMed Inc Scar Drug Details
  6.2.1 Drug Snapshot
    6.2.1.1 Originator
    6.2.1.2 Collaborator/Co-Developer
    6.2.1.3 Route of Administration
    6.2.1.4 Orphan Drug/Fast Track/Special Designation
    6.2.1.5 Area
    6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7. COTINGA PHARMACEUTICALS INC SCAR PIPELINE DETAILS

7.1 Cotinga Pharmaceuticals Inc Business Profile
7.2 Cotinga Pharmaceuticals Inc Scar Drug Details
  7.2.1 Drug Snapshot
    7.2.1.1 Originator
    7.2.1.2 Collaborator/Co-Developer
    7.2.1.3 Route of Administration
    7.2.1.4 Orphan Drug/Fast Track/Special Designation
    7.2.1.5 Area
    7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8. EMBER THERAPEUTICS INC SCAR PIPELINE DETAILS

8.1 Ember Therapeutics Inc Business Profile
8.2 Ember Therapeutics Inc Scar Drug Details
  8.2.1 Drug Snapshot
    8.2.1.1 Originator
    8.2.1.2 Collaborator/Co-Developer
    8.2.1.3 Route of Administration
    8.2.1.4 Orphan Drug/Fast Track/Special Designation
    8.2.1.5 Area
    8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9. KRINGLE PHARMA INC SCAR PIPELINE DETAILS

9.1 Kringle Pharma Inc Business Profile
9.2 Kringle Pharma Inc Scar Drug Details
  9.2.1 Drug Snapshot
    9.2.1.1 Originator
    9.2.1.2 Collaborator/Co-Developer
    9.2.1.3 Route of Administration
    9.2.1.4 Orphan Drug/Fast Track/Special Designation
    9.2.1.5 Area
    9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10. MOERAE MATRIX INC SCAR PIPELINE DETAILS

10.1 Moerae Matrix Inc Business Profile
10.2 Moerae Matrix Inc Scar Drug Details
  10.2.1 Drug Snapshot
    10.2.1.1 Originator
    10.2.1.2 Collaborator/Co-Developer
    10.2.1.3 Route of Administration
    10.2.1.4 Orphan Drug/Fast Track/Special Designation
    10.2.1.5 Area
    10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11. PHARMAXIS LTD SCAR PIPELINE DETAILS

11.1 Pharmaxis Ltd Business Profile
11.2 Pharmaxis Ltd Scar Drug Details
  11.2.1 Drug Snapshot
    11.2.1.1 Originator
    11.2.1.2 Collaborator/Co-Developer
    11.2.1.3 Route of Administration
    11.2.1.4 Orphan Drug/Fast Track/Special Designation
    11.2.1.5 Area
    11.2.1.6 Type of Molecular Entity
11.3 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12. PROMORE PHARMA AB SCAR PIPELINE DETAILS

12.1 Promore Pharma AB Business Profile
12.2 Promore Pharma AB Scar Drug Details
  12.2.1 Drug Snapshot
    12.2.1.1 Originator
    12.2.1.2 Collaborator/Co-Developer
    12.2.1.3 Route of Administration
    12.2.1.4 Orphan Drug/Fast Track/Special Designation
    12.2.1.5 Area
    12.2.1.6 Type of Molecular Entity
12.3 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13. RESOLYS BIO INC SCAR PIPELINE DETAILS

13.1 Resolys Bio Inc Business Profile
13.2 Resolys Bio Inc Scar Drug Details
  13.2.1 Drug Snapshot
    13.2.1.1 Originator
    13.2.1.2 Collaborator/Co-Developer
    13.2.1.3 Route of Administration
    13.2.1.4 Orphan Drug/Fast Track/Special Designation
    13.2.1.5 Area
    13.2.1.6 Type of Molecular Entity
13.3 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14. RXI PHARMACEUTICALS CORP SCAR PIPELINE DETAILS

14.1 RXi Pharmaceuticals Corp Business Profile
14.2 RXi Pharmaceuticals Corp Scar Drug Details
  14.2.1 Drug Snapshot
    14.2.1.1 Originator
    14.2.1.2 Collaborator/Co-Developer
    14.2.1.3 Route of Administration
    14.2.1.4 Orphan Drug/Fast Track/Special Designation
    14.2.1.5 Area
    14.2.1.6 Type of Molecular Entity
14.3 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15. SCARX THERAPEUTICS SCAR PIPELINE DETAILS

15.1 ScarX Therapeutics Business Profile
15.2 ScarX Therapeutics Scar Drug Details
  15.2.1 Drug Snapshot
    15.2.1.1 Originator
    15.2.1.2 Collaborator/Co-Developer
    15.2.1.3 Route of Administration
    15.2.1.4 Orphan Drug/Fast Track/Special Designation
    15.2.1.5 Area
    15.2.1.6 Type of Molecular Entity
15.3 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments

16. SYNEDGEN INC SCAR PIPELINE DETAILS

16.1 Synedgen Inc Business Profile
16.2 Synedgen Inc Scar Drug Details
  16.2.1 Drug Snapshot
    16.2.1.1 Originator
    16.2.1.2 Collaborator/Co-Developer
    16.2.1.3 Route of Administration
    16.2.1.4 Orphan Drug/Fast Track/Special Designation
    16.2.1.5 Area
    16.2.1.6 Type of Molecular Entity
16.3 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments

17. VASCULAR BIOSCIENCES SCAR PIPELINE DETAILS

17.1 Vascular BioSciences Business Profile
17.2 Vascular BioSciences Scar Drug Details
  17.2.1 Drug Snapshot
    17.2.1.1 Originator
    17.2.1.2 Collaborator/Co-Developer
    17.2.1.3 Route of Administration
    17.2.1.4 Orphan Drug/Fast Track/Special Designation
    17.2.1.5 Area
    17.2.1.6 Type of Molecular Entity
17.3 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments

18. LATEST SCAR DRUG PIPELINE DEVELOPMENTS, 2019

19. APPENDIX

19.1 About Us
19.2 Sources and Methodology
19.3 Contact Information